Nostics
Nostics is a medical diagnostics startup that combines photonics and AI to rapidly identify pathogen signatures, aiming to enable quality healthcare through rapid diagnosis. Their technology is based on Nobel-prize winning Raman spectroscopy, advanced nanotechnology, and AI, providing actionable diagnostic results at the point-of-care to ensure the right treatment at the right time. They focus on making diagnostics accessible for everyone, everywhere, and are involved in various applications including pathogen identification and antimicrobial resistance combat.
Industries
Nr. of Employees
small (1-50)
Nostics
Pietersbergweg 199, 1105 BM Amsterdam, The Netherlands
Products
Spectroscopy-based point-of-care diagnostic platform
An instrument combining Raman spectroscopy, nanotechnology and AI to detect and identify bacteria and other pathogens rapidly at the point-of-care, intended to deliver results comparable to laboratory methods within minutes.
Culture-plate (colony) spectral analysis proof-of-concept
A technology proof-point using spectral measurements of bacterial colonies on culture plates to validate detection and classification methods before moving to direct-sample workflows.
Direct UTI identification application
A lead clinical application focused on immediate identification of urinary tract infection pathogens at the point-of-care to enable targeted antibiotic prescribing during the patient visit.
Spectroscopy-based point-of-care diagnostic platform
An instrument combining Raman spectroscopy, nanotechnology and AI to detect and identify bacteria and other pathogens rapidly at the point-of-care, intended to deliver results comparable to laboratory methods within minutes.
Culture-plate (colony) spectral analysis proof-of-concept
A technology proof-point using spectral measurements of bacterial colonies on culture plates to validate detection and classification methods before moving to direct-sample workflows.
Direct UTI identification application
A lead clinical application focused on immediate identification of urinary tract infection pathogens at the point-of-care to enable targeted antibiotic prescribing during the patient visit.
Services
Partnerships and demonstrations to evaluate and validate spectroscopy + AI methods for pathogen identification and to explore joint development or pilots.
Engagement channel for investors and organisations interested in funding or strategic partnerships related to diagnostic platform development.
Partnerships and demonstrations to evaluate and validate spectroscopy + AI methods for pathogen identification and to explore joint development or pilots.
Engagement channel for investors and organisations interested in funding or strategic partnerships related to diagnostic platform development.
Expertise Areas
- Point-of-care diagnostics
- Pathogen identification and spectral fingerprinting
- Spectroscopy-based analytical methods
- AI and machine learning for diagnostic classification
Key Technologies
- Raman spectroscopy
- Nanotechnology-based signal enhancement
- Machine learning (foundation models)
- Few-shot learning
News & Updates
Nostics has attracted Dr Robin Patel, a leader in clinical microbiology, as an advisor to enhance their diagnostic platform.
An article discussing how foundation models are used for bacteria identification and more, highlighting the company's technological advancements.
Nostics has achieved B Corporation certification, emphasizing their commitment to social and environmental responsibility.
Jeroen Nieuwenhuis has been appointed as the new CEO of Nostics, bringing veteran medtech leadership to the company.
Nostics cofounder Rochelle Niemeijer has been recognized in Forbes 30 Under 30 list for Europe in the Healthcare domain.
Nostics has attracted Dr Robin Patel, a leader in clinical microbiology, as an advisor to enhance their diagnostic platform.
An article discussing how foundation models are used for bacteria identification and more, highlighting the company's technological advancements.
Nostics has achieved B Corporation certification, emphasizing their commitment to social and environmental responsibility.
Jeroen Nieuwenhuis has been appointed as the new CEO of Nostics, bringing veteran medtech leadership to the company.
Nostics cofounder Rochelle Niemeijer has been recognized in Forbes 30 Under 30 list for Europe in the Healthcare domain.